Using Digital Pathology to Determine the Role of Tumor-Infiltrating B-Cells in Clinical Outcomes of Patients with Melanoma

Life Sciences, Clinical Trials, Biomarkers,
  • Wednesday, December 15, 2021 | 1pm EST (10am PST)
  • 60 min

Biomarkers are needed to identify patients who benefit most from targeted or immune checkpoint inhibitor (ICI) therapy in metastatic melanoma. This webinar will share an analysis of biomarkers using pre-treatment melanoma samples from the dabrafenib plus trametinib arm of the randomized, Phase III COMBI-v trial using the HALO® image analysis platform combined with gene expression analysis using the Nanostring nCounter technology.

This is believed to be the first large-scale analysis of gene expression signatures, tumor cell interactions and T- and B-cell interactions by digital pathology in patients treated with targeted therapy. Distinct T-cell/B-cell signatures at baseline demonstrated prognostic value, as high T-cell/low B-cell signatures were associated with prolonged survival vs. high T-cell/high B-cell signatures.

Patients with high B-cell signatures had high tumor B-cell infiltration associated with a modified tumor cell phenotype. Recent findings show high T-cell/high B-cell signatures at screening correlated with improved response to ICIs vs. low B-cell signatures. B cells may be potential biomarkers to identify patients who could achieve improved clinical benefit.

Join this webinar to learn:

  • How biomarker analysis with digital pathology coupled with analysis of gene expression can identify T- and B-cell signatures with prognostic value in melanoma
  • How digital image analysis can identify tumor and stroma compartments and perform cell-by-cell analysis of biomarker positivity within the respective compartments to identify and quantify cellular phenotypes
  • How spatial analysis can provide insight into interactions between T- and B-cells

Speaker

http://Ken%20Schultz,%20Novartis

Ken Schultz, Principal Scientist, Novartis

Ken Schultz is a principal scientist in Oncology Translational Research at Novartis. He started with Novartis in 2012 as part of Oncology Precision Medicine. Most recently, he has led the implementation of multiple digital pathology workflows and AI platforms for research and early clinical trial biomarker work. He holds a BS in Biology from Seattle University.

Message Presenter

Who Should Attend?

This webinar is recommended for pathologists, image analysts and research scientists from academia, pharma and CROs interested in:

  • Quantitative assessment of digital pathology images
  • Correlating biomarker and phenotypic analysis to patient outcomes
  • Immune checkpoint inhibitor therapies
  • Designing a clinical trial with a digital pathology endpoint

What You Will Learn

Join this webinar to learn:

  • How biomarker analysis with digital pathology coupled with analysis of gene expression can identify T- and B-cell signatures with prognostic value in melanoma
  • How digital image analysis can identify tumor and stroma compartments and perform cell-by-cell analysis of biomarker positivity within the respective compartments to identify and quantify cellular phenotypes
  • How spatial analysis can provide insight into interactions between T- and B-cells

Xtalks Partner

Indica Labs

Indica Labs software solutions provide fast, quantitative evaluation of whole slide tissues using HALO® and HALO AITM for image analysis and HALO LinkTM and HALO AP® to manage images, data, and facilitate collaboration. With unmatched ease-of-use and scalability, pharmaceutical, healthcare, and research organizations worldwide are using HALO for high-throughput, whole-slide image quantification in areas such as oncology, immuno-oncology, neuroscience, ophthalmology, metabolism, and toxicological pathology.

Media Partner

The original site for employees in the pharma, medical, diagnostic and related industries. Our hand-curated daily news feed and active message forums will keep you informed.

You Must Login To Register for this Free Webinar

Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.

Create Account